506 related articles for article (PubMed ID: 19352131)
1. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
5. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
Obradovic M; Mrhar A; Kos M
Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
[TBL] [Abstract][Full Text] [Related]
8. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
12. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
13. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
14. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
16. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
17. Screening for renal cancer in recipients of kidney transplants.
Wong G; Howard K; Webster AC; Chapman JR; Craig JC
Nephrol Dial Transplant; 2011 May; 26(5):1729-39. PubMed ID: 20961889
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]